The approval expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care. Epinephrine is a non-selective alpha and beta adrenergic agonist.

It will be available tomorrow, day 1 of patent expiry, the Hyderabad-based generic drugmaker said on Friday. Semaglutide is ...

BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has ...

FRANKFURT (Reuters) - The European Union's healthcare regulator will this week review the use of Eli Lilly's approved Mounjaro drug against diabetes and obesity when prefilled in a multi-dose ...

Business Wire India • The novel pen device will be available for patients in a prefilled cartridge administered using a patient-friendly reusable pen for which the comp ...

Natco Pharma has launched the Semaglutide injection in India on the first day of its patent expiry. Hyderabad-based Natco ...

PRINCETON, N.J., Jan. 2, 2019 /PRNewswire/ -- Slayback Pharma LLC announced today that the U.S. Food and Drug Administration ("FDA") granted approval of its abbreviated new drug application ("ANDA") ...

Feb 23 (Reuters) - Eli Lilly said on Monday it received the U.S. Food and ‌Drug Administration's approval to launch a ‌four-dose KwikPen for its weight-loss drug Zepbound, delivering a full month of ...

NATCO Pharma announced the launch of Semaglutide Injection (multi dose vials) in India market tomorrow on Day 1 of patent expiry.

(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced that the U.S. FDA has approved its Epinephrine injection USP, 1 mg/mL, in both single-dose and multi-dose for use in U.S. hospitals.

Zydus Lifesciences on Saturday announced the launch of Semaglutide Injection in India under the brand names SEMAGLYN™, MASHEMA™ and ALTERME™, following patent expiry.